Journal of Biomedical Advancement Scientific Research

Abstract

Oil palm phenolics (OPP) are water-soluble bioactive compounds recovered from aqueous streams generated during palm oil processing, creating an unusual intersection between cardiovascular science, nutraceutical development, and circular bioeconomy. This qualitative literature review critically evaluates contemporary evidence concerning OPP as a potential intervention for early vascular dysfunction and elevated blood pressure. The synthesis integrates OPP chemistry and processing, endothelial pathobiology, phenolic metabolism, mechanistic studies, broader polyphenol evidence, and emerging human trials. OPP contains phenolic constituents including protocatechuic acid, p-hydroxybenzoic acid, hydroxytyrosol, and caffeoylshikimic-acid derivatives. Mechanistically, these compounds may influence oxidative stress, inflammatory signaling, Akt/eNOS-dependent nitric-oxide bioavailability, vascular tone, and endothelial homeostasis. Human evidence has progressed from Phase I safety evaluation to Phase II cardiometabolic studies. Short-term supplementation has generally demonstrated acceptable tolerability, while emerging trials suggest effects on triglycerides in selected hyperlipidemic participants, antioxidant and inflammatory biomarkers, and office blood pressure. Nevertheless, evidence remains insufficient to classify OPP as an antihypertensive intervention. Major uncertainties involve pharmacokinetics, nonlinear dose-response relationships, ambulatory blood pressure, endothelial function, arterial stiffness, long-term safety, drug interactions, and responder heterogeneity. A precision-nutraceutical development framework is proposed integrating standardized chemical fingerprints, metabolomics, microbiome-related metabotypes, biomarker-guided dosing, and clinically meaningful vascular endpoints.